Investors

Event will include guest speaker, Dr. Anthony Mato, Director of the CLL Program at Memorial Sloan Kettering Cancer Center SAN FRANCISCO, May 09, 2022 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc.   (Nasdaq: NRIX), a clinical stage biopharmaceutical company developing targeted protein modulation

Studies provide insight into bifunctional molecular mechanism and first in vivo demonstration of immunomodulatory imide drug (IMiD) activity of NX-2127, resulting in robust tumor cell killing Animal models of adoptive cell therapy support the use of NX-0255 in the production of an investigational

Dosed first patient in the Phase 1 trial of DeTIL-0255, Nurix’s drug-enhanced tumor infiltrating lymphocyte (TIL) program Awarded Innovation Passport for Entry into Innovative Licensing and Access Pathway (ILAP) in the United Kingdom for NX-1607 Reports strong financial position with $385.7 million

First in human study of drug-enhanced tumor infiltrating lymphocyte therapy in patients with gynecological malignancies SAN FRANCISCO, April 05, 2022 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical stage biopharmaceutical company developing targeted protein modulation drugs,

SAN FRANCISCO, April 04, 2022 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc.   (Nasdaq: NRIX), a clinical stage biopharmaceutical company developing targeted protein modulation drugs, today announced that Arthur T. Sands, M.D., Ph.D., Nurix’s president and chief executive officer, will participate in

NX-1607 is being evaluated in multiple immuno-oncology indications, including a range of solid tumor types The ILAP aims to accelerate the time to market for innovative medicines that address the needs of patients with life-threatening or seriously debilitating diseases SAN FRANCISCO, March 29,

SAN FRANCISCO, March 09, 2022 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc.  (Nasdaq: NRIX), a biopharmaceutical company developing targeted protein modulation drugs, today announced that Arthur T. Sands, M.D., Ph.D., Nurix’s president and chief executive officer, will participate in the following

SAN FRANCISCO, March 08, 2022 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc.   (Nasdaq: NRIX), a biopharmaceutical company developing targeted protein modulation drugs, today announced that preclinical data supporting its NX-2127 and DeTIL-0255 clinical programs will be presented at the upcoming

SAN FRANCISCO, Feb. 10, 2022 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc.   (Nasdaq: NRIX), a biopharmaceutical company developing targeted protein modulation drugs, today announced that Arthur T. Sands, M.D., Ph.D., Nurix’s president and chief executive officer, will participate in a fireside chat

Advanced four wholly owned and internally developed programs into clinical development Strengthened balance sheet with year-end cash and investments totaling $433 million Anticipate multiple clinical milestones in 2022 SAN FRANCISCO, Jan. 27, 2022 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc.